Genomic profiling reveals mutational landscape in parathyroid carcinomas

Parathyroid carcinoma (PC) is an extremely rare malignancy lacking effective therapeutic intervention. We generated and analyzed whole-exome sequencing data from 17 patients to identify somatic and germline genetic alterations. A panel of selected genes was sequenced in a 7-tumor expansion cohort. W...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JCI insight 2017-03, Vol.2 (6), p.e92061-e92061
Hauptverfasser: Pandya, Chetanya, Uzilov, Andrew V, Bellizzi, Justin, Lau, Chun Yee, Moe, Aye S, Strahl, Maya, Hamou, Wissam, Newman, Leah C, Fink, Marc Y, Antipin, Yevgeniy, Yu, Willie, Stevenson, Mark, Cavaco, Branca M, Teh, Bin T, Thakker, Rajesh V, Morreau, Hans, Schadt, Eric E, Sebra, Robert, Li, Shuyu D, Arnold, Andrew, Chen, Rong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Parathyroid carcinoma (PC) is an extremely rare malignancy lacking effective therapeutic intervention. We generated and analyzed whole-exome sequencing data from 17 patients to identify somatic and germline genetic alterations. A panel of selected genes was sequenced in a 7-tumor expansion cohort. We show that 47% (8 of 17) of the tumors harbor somatic mutations in the tumor suppressor, with germline inactivating variants in 4 of the 8 patients. The PI3K/AKT/mTOR pathway was altered in 21% of the 24 cases, revealing a major oncogenic pathway in PC. We observed amplification in 29% of the 17 patients, and a previously unreported recurrent mutation in putative kinase . We identified the first sporadic PCs with somatic mutations in the Wnt canonical pathway, complementing previously described epigenetic mechanisms mediating Wnt activation. This is the largest genomic sequencing study of PC, and represents major progress toward a full molecular characterization of this rare malignancy to inform improved and individualized treatments.
ISSN:2379-3708
2379-3708
DOI:10.1172/jci.insight.92061